Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy: Results of a prospective feasibility study in advanced lung cancer in the okayama lung cancer study group trial 1002

Japanese Journal of Clinical Oncology

Volumn 43, Issue 11, 2013, Pages 1115-1123

  Hotta, Katsuyuki ^a   Takigawa, Nagio ^a,b   Hisamoto Sato, Akiko ^a   Ichihara, Eiki ^a   Kudo, Kenichiro ^a   Uchida, Koji ^a   Yanase Nakamura, Kayo ^a   Tanaka, Hisaaki ^a   Kato, Yuka ^a   Tabata, Masahiro ^a   Tanimoto, Mitsune ^a   Kiura, Katsuyuki ^a  

^a OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^b Kawasaki Hospital   (Japan)

Author keywords

Cisplatin; Hydration; Lung cancer

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; IRINOTECAN; NAVELBINE; PEMETREXED;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CONSTIPATION; CREATININE CLEARANCE; DIARRHEA; DISEASE COURSE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; HYDRATION; JAPAN; KIDNEY FUNCTION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PERFORMANCE; PROSPECTIVE STUDY; VOMITING;

CISPLATIN; HYDRATION; LUNG CANCER;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CISPLATIN; CREATININE; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; FLUID THERAPY; HUMANS; JAPAN; KIDNEY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84887072071     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyt128     Document Type: Article

References (20)

1. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004;22:3852-9.
2. Hotta K, Matsuo K. Long-standing debate on cisplatin- versus carboplatin-based chemotherapy in the treatment of advanced non-small-cell lung cancer. J Thorac Oncol 2007;2:96.
3. Hotta K, Fujiwara Y, Matsuo K, Suzuki T, Kiura K, Tabata M, et al. Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy. Cancer 2007;109:939-48.
4. Oze I, Hotta K, Kiura K, Ochi N, Takigawa N, Fujiwara Y, et al. Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results. PLoS One 2009;4:e7835.
5. Rossi A, Di Maio M, Chiodini P, Rudd RM, Okamoto H, Skarlos DV, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol 2012;30:1692-8.
6. Stewart DJ, Dulberg CS, Mikhael NZ, Redmond MD, Montpetit VA, Goel R. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods. Cancer Chemother Pharmacol 1997;40:293-308.
7. Pera MF, Jr, Zook BC, Harder HC. Effects of mannitol or furosemide diuresis on the nephrotoxicity and physiological disposition of cis-dichlorodiammineplatinum-(II) in rats. Cancer Res 1979;39:1269-78.
8. Ostrow S, Egorin MJ, Hahn D, Markus S, Aisner J, Chang P, et al. High-dose cisplatin therapy using mannitol versus furosemide diuresis: comparative pharmacokinetics and toxicity. Cancer Treat Rep 1981;65:73-8.
9. Sekine I, Kubota K, Tamura Y, Asahina H, Yamada K, Horinouchi H, et al. Innovator and generic cisplatin formulations: comparison of renal toxicity. Cancer Sci 2011;102:162-5.
10. Tiseo M, Martelli O, Mancuso A, Sormani MP, Bruzzi P, Di Salvia R, et al. Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma. Tumori 2007;93:138-44.
11. Brock J, Alberts DS. Safe, rapid administration of cisplatin in the outpatient clinic. Cancer Treat Rep 1986;70:1409-14.
12. Vogl SE, Zaravinos T, Kaplan BH. Toxicity of cis-diamminedichloroplatinum II given in a two-hour outpatient regimen of diuresis and hydration. Cancer 1980;45:11-5.
13. Chiuten D, Vogl S, Kaplan B, Camacho F. Is there cumulative or delayed toxicity from cis-platinum? Cancer 1983;52:211-4.
14. Sekine I, Yamada K, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y, et al. Bodyweight change during the first 5 days of chemotherapy as an indicator of cisplatin renal toxicity. Cancer Sci 2007;98:1408-12.
15. Hotta K, Sekine I, Tamura T, Sawada M, Watanabe H, Kusaba H, et al. A phase I/II study of cisplatin and vinorelbine chemotherapy in patients with advanced non-small cell lung cancer. Jpn J Clin Oncol 2001;31:596-600.
16. Gridelli C, Maione P, Rossi A, Guerriero C, Ferrara C, Del Gaizo F, et al. Chemotherapy of advanced NSCLC in special patient population. Ann Oncol 2006;17:v72-8.
17. Billingham L, Cullen M. The benefits of chemotherapy in patient subgroups with unresectable non-small-cell lung cancer. Ann Oncol 2001;12:1671-1675.
18. Hotta K, Kiura K, Takigawa N, Suzuki E, Yoshioka H, Okada T, et al. Association between poor performance status and risk for toxicity during erlotinib monotherapy in Japanese patients with non-small cell lung cancer: Okayama Lung Cancer Study Group experience. Lung Cancer 2010;70:308-312.
19. Ochi N, Hotta K, Takigawa N, Oze I, Fujiwara Y, Ichihara E, et al. Treatment-related death in patients with small-cell lung cancer in phase III trials over the last two decades. PLoS One 2012;7:e42798.
20. Fujiwara Y, Hotta K, Di Maio M, Kiura K, Takigawa N, Tabata M, et al. Time trend in treatment-related deaths of patients with advanced non-small-cell lung cancer enrolled into phase III trials of systemic treatment. Ann Oncol 2011;22:376-82.